Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study
Authors:
- Steven G. ChrysantSCSteven G. Chrysant
- Joseph L. IzzoJIJoseph L. Izzo
- Dean J. KereiakesDKDean J. Kereiakes
- Thomas LittlejohnTLThomas Littlejohn
- Suzanne OparilSOSuzanne Oparil
- Michael MelinoMMMichael Melino
- James LeeJLJames Lee
- Victor FernandezVFVictor Fernandez
- Reinilde HeyrmanRHReinilde Heyrman
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 6 (2) , 132-141
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group studyClinical Therapeutics, 2010
- US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008JAMA, 2010
- Treatment of hypertension in patients with diabetes—an updateJournal of the American Society of Hypertension, 2010
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational studyBMJ, 2000
- Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes MellitusNew England Journal of Medicine, 2000
- Risk Factors for Stroke in Type 2 Diabetes MellitusArchives of internal medicine (1960), 1999
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 1998
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998